SM
BLCM

Sabby Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Sabby Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-293
Closed -$5.93M – 366
2015
Q4 		$5.93M Buy
293
+240
+453% +$42.9K 0.33% 54
2015
Q3 		$764K Buy
53
+37
+231% +$6.79K 0.03% 268
2015
Q2 		$342K Buy
+16
New +$3.92K 0.01% 273

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Sabby Management's BLCM Position: Q1 2021 in Review

Sabby Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2021, closing a stake of 159,500 shares — an estimated $563K sold.

Sabby Management first reported a position in BLCM in Q4 2014 and held it in 9 quarters. The position peaked at $5.36M in Q1 2015. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2021.

  • Sabby Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 159,500 Bellicum Pharmaceuticals, Inc. shares in Q1 2021, an estimated $563K.
  • Sabby Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
  • Sabby Management's Bellicum Pharmaceuticals, Inc. position peaked at $5.36M in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.